Perthera Closes $8.7 Million Series A Financing Round
Tuesday, June 28, 2016
Perthera, Inc just completed an $8.7 Million Series A financing round. This round was led by Pilot Growth Equity, a technology growth equity firm with offices in San Francisco, New York and Washington, DC.
Launched in 2013 by George Mason University researcher Emanuel Petricoin and venture capitalist Dendy Young, McLean, Virginia-based Perthera provides molecular profiling of cancer patients to help physicians guide their treatments.
“The rapid progress being achieved in the field of precision medicine offers the very real promise of more successful new treatments for cancer. But a precise understanding of an individual’s particular cancer tumor is a prerequisite to the use of precision medicines, and that’s what a PCA can provide,” said Petricoin. “We do that by using the most sophisticated and comprehensive molecular analysis available. Although genomic testing has proven to be a breakthrough technology, an even more comprehensive portrait of a patient’s cancer can be obtained through our multi-omic analysis. Our unique workflow protects tissue, utilizes best-in-class molecular testing, and leverages our unique and growing databank of previous treatment histories and patient outcomes. The PCA is becoming a critical part of the future of cancer treatment,” Petricoin added.
The company is also developing a database of patient treatment histories and outcomes to help guide future patient treatments.